BCL2L1 and colonic neoplasm: In our study, using a different Bcl-xL AS oligonucleotide sequence in a different colon cancer cell line, the chemosensitisation approach was successfully extended to a more than 70% reduction of cell viability in combination with the cytotoxic chemotherapeutic agent cisplatin.